Hereditary leiomyomatosis and renal cell cancer

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a disorder in which affected individuals tend to develop benign tumors containing smooth muscle tissue (leiomyomas) in the skin and, in females, the uterus. This condition also increases the risk of kidney cancer.

In this disorder, growths on the skin (cutaneous leiomyomas) typically develop in the third decade of life. Most of these growths arise from the tiny muscles around the hair follicles that cause "goosebumps". They appear as bumps or nodules on the trunk, arms, legs, and occasionally on the face. Cutaneous leiomyomas may be the same color as the surrounding skin, or they may be darker. Some affected individuals have no cutaneous leiomyomas or only a few, but the growths tend to increase in size and number over time. Cutaneous leiomyomas are often more sensitive than the surrounding skin to cold or light touch, and may be painful.

Most women with HLRCC also develop uterine leiomyomas (fibroids). While uterine fibroids are very common in the general population, women with HLRCC tend to have numerous large fibroids that appear earlier than in the general population.

Approximately 10 percent to 16 percent of people with HLRCC develop a type of kidney cancer called renal cell cancer. The signs and symptoms of renal cell cancer may include lower back pain, blood in the urine, or a mass in the kidney that can be felt upon physical examination. Some people with renal cell cancer have no symptoms until the disease is advanced. People with HLRCC are commonly diagnosed with kidney cancer in their forties.

This disorder, especially if it appears in individuals or families without renal cell cancer, is also sometimes called multiple cutaneous leiomyomatosis (MCL) or multiple cutaneous and uterine leiomyomatosis (MCUL).

Frequency

HLRCC is a rare condition that has been reported in approximately 300 families worldwide. Researchers suggest that it may be under-diagnosed.

Genetic Changes

Mutations in the FH gene cause HLRCC. The FH gene provides instructions for making an enzyme called fumarase (also known as fumarate hydratase). This enzyme participates in an important series of reactions known as the citric acid cycle or Krebs cycle, which allows cells to use oxygen and generate energy. Specifically, fumarase helps convert a molecule called fumarate to a molecule called malate.
People with HLRCC are born with one mutated copy of the \( FH \) gene in each cell. The second copy of the \( FH \) gene in certain cells may also acquire mutations as a result of environmental factors such as ultraviolet radiation from the sun or an error that occurs as DNA copies itself during cell division.

\( FH \) gene mutations may interfere with the enzyme's role in the citric acid cycle, resulting in a buildup of fumarate. Researchers believe that the excess fumarate may interfere with the regulation of oxygen levels in the cell. Chronic oxygen deficiency (hypoxia) in cells with two mutated copies of the \( FH \) gene may encourage tumor formation and result in the tendency to develop leiomyomas and renal cell cancer.

**Inheritance Pattern**

This condition is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder.

In some cases, an affected person inherits the mutation from one affected parent. Other cases result from new mutations in the gene and occur in people with no history of the disorder in their family.

Children born with two mutated copies of the \( FH \) gene in each cell have a different condition called fumarase deficiency, which is often fatal in infancy. These individuals inherit one mutated copy of the gene from each parent. People with HLRCC can contribute one mutated copy of the gene to a child and are potential carriers of fumarase deficiency, but they do not have signs or symptoms of that condition.

**Other Names for This Condition**

- hereditary leiomyomatosis and renal cell carcinoma
- HLRCC
- leiomyomatosis and renal cell cancer
- LRCC
- MCL
- MCUL
- multiple cutaneous and uterine leiomyomata
- multiple cutaneous leiomyoma
- Reed's syndrome

**Diagnosis & Management**

**Genetic Testing**

- Genetic Testing Registry: Hereditary leiomyomatosis and renal cell cancer
Other Diagnosis and Management Resources

- GeneReview: Hereditary Leiomyomatosis and Renal Cell Cancer
  https://www.ncbi.nlm.nih.gov/books/NBK1252
- MedlinePlus Encyclopedia: Renal Cell Carcinoma
  https://medlineplus.gov/ency/article/000516.htm

General Information from MedlinePlus

- Diagnostic Tests
  https://medlineplus.gov/diagnostictests.html
- Drug Therapy
  https://medlineplus.gov/drugtherapy.html
- Genetic Counseling
  https://medlineplus.gov/geneticcounseling.html
- Palliative Care
  https://medlineplus.gov/palliativecare.html
- Surgery and Rehabilitation
  https://medlineplus.gov/surgeryandrehabilitation.html

Additional Information & Resources

MedlinePlus

- Encyclopedia: Renal Cell Carcinoma
  https://medlineplus.gov/ency/article/000516.htm
- Health Topic: Kidney Cancer
  https://medlineplus.gov/kidneycancer.html
- Health Topic: Uterine Fibroids
  https://medlineplus.gov/uterinefibroids.html

Genetic and Rare Diseases Information Center

- Hereditary leiomyomatosis and renal cell cancer

Additional NIH Resources

- Eunice Kennedy Shriver National Institute of Child Health and Human Development: Uterine Fibroids
  https://www.nichd.nih.gov/health/topics/uterine
- National Cancer Institute: Renal Cell Cancer
Educational Resources

- American Cancer Society
- Disease InfoSearch: Leiomyomatosis and renal cell cancer, hereditary
  http://www.diseaseinfosearch.org/Leiomyomatosis+and+renal+cell+cancer%2C+hereditary/4161
- Kidney Cancer Association
  https://www.survivekidneycancer.com/
- MalaCards: leiomyomatosis and renal cell cancer
  http://www.malacards.org/card/leiomyomatosis_and_renal_cell_cancer
- My46 Trait Profile
- Orphanet: Hereditary leiomyomatosis and renal cell cancer
  http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=523

Patient Support and Advocacy Resources

- HLRCC Family Alliance
  http://hlrccinfo.org/
- National Organization for Rare Disorders (NORD): Renal Cell Carcinoma
  https://rarediseases.org/rare-diseases/renal-cell-carcinoma/

GeneReviews

- Hereditary Leiomyomatosis and Renal Cell Cancer
  https://www.ncbi.nlm.nih.gov/books/NBK1252

ClinicalTrials.gov

- ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22hereditary+leiomyomatosis+and+renal+cell+cancer%22

Scientific Articles on PubMed

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28renal+cell+cancer%5BTIAB%5D%29+OR+%28renal+cell+carcinoma%5BTIAB%5D%29+AND+%28leiomyomatosis%5BTIAB%5D%29+OR+%28hlrcc%5BTIAB%5D%29+OR+%28lrcc%5BTIAB%5D%29+OR+%28mcl%5BTIAB%5D%29+OR+%28mcul%5BTIAB%5D%29+OR+%28multiple+cutaneous+leiomyoma%5BTIAB%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+3600+days%22%5Bdp%5D
OMIM

• HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER
  http://omim.org/entry/150800

MedGen

• Hereditary leiomyomatosis and renal cell cancer

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28195105

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28400389

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27566483

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25012257
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574691/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25012257
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574691/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28314682

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25018647
  Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074185/

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28122802

Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28196407


Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24526232

Reprinted from Genetics Home Reference:

Reviewed: February 2018
Published: March 13, 2018

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services